Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.43 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.43 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.43 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.43 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.43 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.43 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.43 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.43 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9380185 | 0.90 | GLA (0.51) | GLASTING1KDM4EATP1A1ATP1B1 | |
| SCHEMBL8714340 | 0.88 | KDM4E (0.59) | GLAKDM4ECYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4013917 | 0.87 | SLC11A2 (0.52) | GLASTING1KDM4ESLC11A2CYP3A4 | |
| SCHEMBL9160788 | 0.75 | CYP1A2 (0.40) | GLASTING1KDM4ECYP3A4MAPT | |
| SCHEMBL7962346 | 0.74 | ALOX5 (0.54) | GLAKDM4ESLC11A2CYP19A1CYP11B1 | |
| SCHEMBL3691280 | 0.73 | SLC11A2 (0.82) | GLASTING1KDM4ESLC11A2ALDH1A1 | |
| SCHEMBL4166534 | 0.73 | SLC11A2 (0.41) | SLC11A2 | |
| SCHEMBL15678569 | 0.72 | LOXL2 (0.50) | GLASTING1KDM4EATP1A1ATP1B1 | |
| Bromide SCHEMBL4154083 | 0.72 | SLC11A2 (0.80) | GLASTING1KDM4EATP1A1ATP1B1 | |
| SCHEMBL9635576 | 0.72 | CYP2D6 (0.38) | CYP3A4LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061755-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
| EP-0278176-B1 | Compounds having antitumour and antibacterial properties | WARNER LAMBERT CO (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5281620-A | Alkyl substituted xanthenone-4-acetic acid | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-01-25 | — | — | US | disclosed |
| EP-0278176-A2 | Compounds having antitumour and antibacterial properties | WARNER-LAMBERT COMPANY (US) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | GLA 2542/4885STING1 3841/4885KDM4E 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.